Jingquan Zhong

Prof. Dr. Jingquan Zhong

Cheeloo college of Shandong Univesity, Jinan, Shandong, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2020 in IEEE Transactions on Instrumentation and Measurement
Verified
Journal Article
Closed access
CMCaiyun Ma
Caiyun Ma
SWShoushui Wei
Shoushui Wei
CTChen TongShuai
Chen TongShuai
JZJingquan Zhong
Jingquan Zhong
ZLZhenhua Liu
Zhenhua Liu
CLChengyu Liu
Chengyu Liu
Atrial fibrillation (AF) can cause a variety of heart diseases and its detection is insufficient in outside hospital. We proposed three methods for AF diagnosis in ambulatory settings. The first method is a convolutional neural network (CNN) trained on modified frequency slice wavelet transform (MFSWT) data. The second is a support vector machine (SVM) classifier trained on multiple AF features data. The third method is an SVM trained on the same feature set but extended by the predictive probability of the CNN. The proposed method (the third one) achieved the highest detection accuracy. MIT-BIH AF database was used as a training set with an accuracy of 97.87% for 30-s ECG episodes and 96.09% for 10-s ECG episodes from fivefold cross-validation. The trained model was tested on the PhysioNet/Computing in Cardiology (CinC) Challenge 2017 database, achieving an accuracy of 93.21% for 30-s episodes and 93.03% for 10-s ECG episodes. When tested on the China Physiological Signal Challenge (CPSC) 2018 database, the corresponding accuracies were 98.48% and 98.61%. The results on the wearable ECGs from a clinical AF patient were 99.21% and 97.04%. We retrained the model on the PhysioNet/CinC Challenge 2017 data set and tested on the other database to explore the generalization ability of the proposed method. Corresponding test results on the MIT-BIH AF database showed accuracies of 96.84% and 95.13%, on the CPSC 2018 database were 96.21% and 98.45%, on the wearable ECGs were 99.08% and 96.43%. The results proved that the proposed method could provide high accuracy and reliable recognition for AF events.

6 October 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
JZJingquan Zhong
Jingquan Zhong
DLDeyong Long
Deyong Long
CHChu Huimin
Chu Huimin
FHFu Hua
Fu Hua
HXHan Xuebin
Han Xuebin
LBLuigi Di Biase
Luigi Di Biase
In recent years, percutaneous catheter interventions have continuously evolved, becoming an essential strategy for interventional diagnosis and treatment of many structural heart diseases and arrhythmias. Along with the increasing complexity of cardiac interventions comes ever more complex demands for intraoperative imaging. Intracardiac echocardiography (ICE) is well-suited for these requirements with real-time imaging, real-time monitoring for intraoperative complications, and a well-tolerated procedure. As a result, ICE is increasingly used many types of cardiac interventions. Given the lack of relevant guidelines at home and abroad and to promote and standardize the clinical applications of ICE, the members of this panel extensively evaluated relevant research findings, and they developed this consensus document after discussions and correlation with front-line clinical work experience, aiming to provide guidance for clinicians and to further improve interventional cardiovascular diagnosis and treatment procedures.

1 August 2025 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
Shaojie ChenShaojie Chen
Shaojie Chen
SNSanjiv M. Narayan
Sanjiv M. Narayan
SBSerge Boveda
Serge Boveda
KNKars Neven
Kars Neven
MRMartin H. Ruwald
Martin H. Ruwald
HPHelmut Purerfellner
Helmut Purerfellner
Pulsed field ablation (PFA) has been developed as a largely nonthermal ablation technology with a unique biophysical profile to treat atrial fibrillation. Existing evidence has shown that PFA offers a safe and efficient atrial fibrillation ablation procedure. Among different PFA technologies, the pentaspline FARAPULSE system has been the most extensively used and investigated; however, notable variability exists in workflow, fluoroscopy time, and lesion durability. While innovations such as 3-dimensional electroanatomic mapping systems and intracardiac echocardiography can enhance procedural precision in catheter ablation, fluoroscopy remains the primary imaging modality for guiding pentaspline PFA in many electrophysiology labs worldwide. This is particularly true in centers where limitations in cost, infrastructure, or training may preclude the routine use of advanced imaging technologies. This article summarizes general practical considerations and presents a primarily fluoroscopy-based, refined workflow developed by a group of experts. The goal is to provide a procedural foundation and practical guide for using the pentaspline FARAPULSE PFA system in atrial fibrillation ablation procedures. Developing a fluoroscopy-based practical guide would: (1) Democratize access to PFA technology, enabling safe and effective implementation across a broader range of clinical settings, including those without intracardiac echocardiography or 3-dimensional mapping support; (2) Reduce procedural heterogeneity by offering reproducible best practices; (3) Facilitate meaningful intercenter comparisons of procedural efficacy and safety, aiding in the identification of optimal approaches and improving the quality of clinical data for ongoing research, registries, and real-world performance monitoring of PFA technologies; and (4) Ultimately improve patient outcomes through standardized, accessible, and evidence-based practices.

4 July 2018 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
LHLi Hao
Li Hao
MRManyi Ren
Manyi Ren
BRBing Rong
Bing Rong
FXFei Xie
Fei Xie
MLMing‐Jie Lin
Ming‐Jie Lin
JZJingquan Zhong
Jingquan Zhong
Atrial myocyte hypertrophy is one of the most important substrates in the development of atrial fibrillation (AF). The TWEAK/Fn14 axis is a positive regulator of cardiac hypertrophy in cardiomyopathy. This study therefore investigated the effects of Fn14 on atrial hypertrophy and underlying cellular mechanisms using HL‐1 atrial myocytes. In patients with AF, Fn14 protein levels were higher in atrial myocytes from atrial appendages, and expression of TWEAK was increased in peripheral blood mononuclear cells, while TWEAK serum levels were decreased. In vitro, Fn14 expression was up‐regulated in response to TWEAK treatment in HL‐1 atrial myocytes. TWEAK increased the expression of ANP and Troponin T, and Fn14 knockdown counteracted the effect. Inhibition of JAK2, STAT3 by specific siRNA attenuated TWEAK‐induced HL‐1 atrial myocytes hypertrophy. In conclusion, TWEAK/Fn14 axis mediates HL‐1 atrial myocytes hypertrophy partly through activation of the JAK2/STAT3 pathway.

17 January 2020 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
LLLingxing Li
Lingxing Li
ZDZhenlan Du
Zhenlan Du
BRBing Rong
Bing Rong
DZDapeng Zhao
Dapeng Zhao
AWAiping Wang
Aiping Wang
JZJingquan Zhong
Jingquan Zhong
Background: Atherosclerosis is a chronic inflammatory disease that contributes to multiple cardiovascular diseases (CVDs), and foam cell formation plays important roles in the progression of atherosclerosis. There is an urgent need to identify new molecular targets for treating atherosclerosis, and thereby improve the quality of life and reduce the financial burden of individuals with CVD. Methods: An in vitro model of atherosclerosis was generated by treating THP-1 cells and human aortic vascular smooth muscle cells (HA-VSMCs) with oxidized low density lipoproteins (ox-LDLs). HA-VSMC proliferation and foam cell formation were detected by the MTT assay and Oil Red O staining. CXCL12 expression was suppressed by siRNA. An atherosclerosis rat model was established by feeding rats a high-fat diet and vitamin D2 for 3 weeks. Histopathology examinations were conducted by H&E staining and the levels ionized calcium-binding adapter molecule 1 (IBA1) and alpha smooth muscle actin (α-SMA) expression were determined by ELISA assays and immunohistochemistry. Results: An in vitro model of atherosclerosis was established with THP-1 cells. CXCL12 expression in the model THP-1 cells was significantly increased when compared with its expression in control cells. Suppression of CXCL12 expression reduced the progression of atherosclerosis in the cell model. Moreover, CXCL12 promoted atherosclerosis in the in vivo rat model. Conclusions: Our results suggest that CXCL12 plays an important role in promoting the progression of atherosclerosis. Furthermore, inhibition of CXCL12 might suppress the development of atherosclerosis by inhibiting HA-VSMC proliferation and their transformation to foam cells.

1 March 2024 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
THTong Hu
Tong Hu
CCChangli Chen
Changli Chen
KMKellina Maduray
Kellina Maduray
WHWenqiang Han
Wenqiang Han
CTChen TongShuai
Chen TongShuai
JZJingquan Zhong
Jingquan Zhong
Background and objective: Left ventricular thrombus (LVT) formation in patients with acute myocardial infarction (AMI) or cardiomyopathies is not uncommon. The optimal oral anticoagulation therapy for resolving LVT has been under intense debate. Vitamin K antagonists (VKAs) remain the anticoagulant of choice for this condition, according to practice guidelines. Evidence supporting the use of direct oral anticoagulants (DOACs) in the management of LVT continues to grow. We performed a systematic review and meta-analysis to compare the efficacy and safety of DOACs versus VKAs. Methods: A comprehensive literature search was carried out in PubMed, Cochrane Library, Web of Science, Embase, and Scopus databases in July 2023. The efficacy outcomes of this study were thrombus resolution, ischemic stroke, systemic embolism, stroke/systemic embolism, all-cause mortality, and adverse cardiovascular events. The safety outcomes were any bleeding, major bleeding, and intracranial hemorrhage. A total of twenty-seven eligible studies were included in the meta-analysis. Data were analyzed utilizing Stata software version 15.1. Results: There was no significant difference between DOACs and VKAs with regard to LVT resolution (RR = 1.00, 95% CI 0.95–1.05, P = 0.99). In the overall analysis, DOACs significantly reduced the risk of stroke (RR = 0.74, 95% CI 0.57–0.96, P = 0.021), all-cause mortality (RR = 0.70, 95% CI 0.57–0.86, P = 0.001), any bleeding (RR = 0.75, 95% CI 0.61–0.92, P = 0.006) and major bleeding (RR = 0.67, 95% CI 0.52–0.85, P = 0.001) when compared to VKAs. Meanwhile, in the sub-analysis examining randomized controlled trials (RCTs), the aforementioned outcomes no longer differed significantly between the DOACs and VKAs groups. The incidences of systemic embolism (RR = 0.81, 95% CI 0.54–1.22, P = 0.32), stroke/systemic embolism (RR = 0.85, 95% CI 0.72–1.00, P = 0.056), intracranial hemorrhage (RR = 0.59, 95% CI 0.23–1.54, P = 0.28), and adverse cardiovascular events (RR = 0.99, 95% CI 0.63–1.56, P = 0.92) were comparable between the DOACs and VKAs groups. A subgroup analysis showed that patients treated with rivaroxaban had a significantly lower risk of stroke (RR = 0.24, 95% CI 0.08–0.72, P = 0.011) than those in the VKAs group. Conclusion: With non-inferior efficacy and superior safety, DOACs are promising therapeutic alternatives to VKAs in the treatment of LVT. Further robust investigations are warranted to confirm our findings.